Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Blueprint Medi Cm ST (BPMC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 1,720,426
  • Shares Outstanding, K 38,130
  • Annual Sales, $ 27,770 K
  • Annual Income, $ -72,500 K
  • 36-Month Beta 1.33
  • Price/Sales 63.15
  • Price/Cash Flow 0.00
  • Price/Book 6.97

Price Performance

See More
Period Period Low Period High Performance
1-Month
39.00 +19.21%
on 03/30/17
47.40 -1.92%
on 04/20/17
+2.53 (+5.76%)
since 03/24/17
3-Month
32.31 +43.89%
on 01/25/17
47.40 -1.92%
on 04/20/17
+13.67 (+41.65%)
since 01/24/17
52-Week
13.27 +250.34%
on 05/06/16
47.40 -1.92%
on 04/20/17
+27.72 (+147.68%)
since 04/22/16

Most Recent Stories

More News
Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced the closing of its previously...

BPMC : 46.49 (+3.04%)
Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced the pricing of an underwritten...

BPMC : 46.49 (+3.04%)
Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that it has commenced an...

BPMC : 46.49 (+3.04%)
Blueprint Medicines to Present on BLU-285 and BLU-554 at Upcoming Scientific Conferences

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that it will present on...

BPMC : 46.49 (+3.04%)
BPMC Crosses Above Average Analyst Target

In recent trading, shares of Blueprint Medicines Corp have crossed above the average analyst 12-month target price of $42.75, changing hands for $43.96/share. When a stock reaches the target an analyst...

BPMC : 46.49 (+3.04%)
3 Biotech Stocks That Are Broker Favorites

These 3 biotech stocks have been given a Strong Buy or Buy rating by 80% or more brokers and sport a favorable Zacks Rank #1 (Strong Buy) or #2 (Buy).

BPMC : 46.49 (+3.04%)
AMGN : 163.14 (+1.70%)
MATN : 0.7500 (-3.86%)
BIIB : 276.86 (+1.44%)
CLLS : 23.31 (+2.91%)
Can The Uptrend Continue for Blueprint Medicines (BPMC)?

Investors certainly have to be happy with Blueprint Medicines Corporation (BPMC) and its short term performance

BPMC : 46.49 (+3.04%)
Blueprint Medicines Reports Fourth Quarter and Full Year 2016 Financial Results

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today reported financial results and provided...

BPMC : 46.49 (+3.04%)
Should You Buy Blueprint Medicines (BPMC) Ahead of Earnings?

Investors are always looking for stocks that are poised to beat at earnings season and Blueprint Medicines Corporation (BPMC) may be one such company.

BPMC : 46.49 (+3.04%)
Blueprint Medicines to Report Fourth Quarter and Full Year 2016 Financial Results on Thursday, March 9, 2017

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that it will host a live...

BPMC : 46.49 (+3.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Blueprint Medicines Corp is an oncology company which is engaged in developing kinase inhibitors for genomically defined cancer subsets. Blueprint Medicines Corp is based in Cambridge, MA.

See More

Support & Resistance

2nd Resistance Point 47.79
1st Resistance Point 47.14
Last Price 46.49
1st Support Level 45.68
2nd Support Level 44.87

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.